Product pipeline and R&Dmixed · 4 filings
“Compensation expenses, including non-cash stock-based compensation, also increased as a result of additional research and development headcount.”10-Q · May 6, 2026 ↗
Taysha Gene Therapies, Inc.
TSHA
Market read
Taysha Gene Therapies, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
Company-5.4% todayVolume comparison unavailable
Market group0 of 19 activeBiotech and Materials · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- TSHA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if TSHA's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- TSHA's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods4
Price observations319
Usable filing statements67
Verified relationships2
Evidence supporting the case
- Latest annual revenue changed +17.3% year over year.
- Product pipeline and R&D has repeated favorable evidence across 4 filings.
Evidence challenging the case
- Operating margin changed -33.1 percentage points in the latest annual period.
- Net margin changed -43.6 percentage points in the latest annual period.
- Diluted shares increased 27.8% in the latest annual period.
Questions before a position
- EV/sales is 1516% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
5.156m+13.7%12m+73.4%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2022-12-31$2.5M—$-3.78—
2023-12-31$15.5M+517.5%$-0.96—
2024-12-31$8.3M-46.1%$-0.36—
2025-12-31$9.8M+17.3%$-0.34+27.8%
What management says matters
Persistent and emerging business drivers
Credit and interest ratesmixed · 2 filings
“No interest expense was recorded on the term loans for the three months ended March 31, 2026 and 2025 due to the election of the fair value option.”10-Q · May 6, 2026 ↗
Restructuring and cost reductionsnegative · 2 filings
“The net loss of $89.3 million was partially offset by $20.5 million in adjustments for non-cash items and other adjustments to reconcile net loss to net cash used in operating activities, primarily due to stock-based compensation expense and impairment of lon…”10-K · Mar 19, 2026 ↗
Legal and regulatory exposuremixed · 1 filings
“The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government and regulatory authorities in the Un…”10-K · Mar 19, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 168.5× · EV/sales 140.9×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
5.04-5.4% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 12:10 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for TSHA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for TSHA. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind TSHA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TRINTrinity Capital Inc.lenderMay 6, 2026 ▾
“Note 7 – Term Loans 2025 Loan with Trinity Capital On August 7, 2025 (the “Trinity Refinance Date”), the Company entered into a Loan and Security Agreement (the “2025 Trinity Term Loan Agreement”), by and among the Company, the lenders party thereto from time…”
Depended on by
RGNXREGENXBIO Inc.competitorMar 5, 2026 ▾
“Competition We are aware of a number of companies focused on developing and commercializing gene therapies in various disease indications, including 4D Molecular Therapeutics, Inc., Amicus Therapeutics, Inc., Astellas Pharma, BioMarin Pharmaceutical, Inc., Li…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TSHA is currently a Leader in the organic co-movement group Biotech and Materials. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for TSHA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.